Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Sponsor
Damanhour University
Study ID
NCT06065280
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 10 MG — DRUG
    Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
  • Dapagliflozin 10 MG — DRUG
    Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.

Study Details

The aim of this study is to assess the efficacy, safety and cardiovascular outcomes of Sodium-glucose transport protein 2 inhibitors (SGLT2i) therapy in patients with heart failure reduced ejection fraction ( HFrEF) with and without diabetes mellitus and is to evaluate short-term effect of these drugs using the cardiac biomarkers Neopterin.

Key Dates

Start date
Nov 1, 2022
Status verified
Feb 2025
Primary completion
Dec 1, 2024
Completion
Dec 30, 2024

Study Design

Enrollment
80 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Diabetic/HFrEF Group
    40 patients with diabetes mellitus patients will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin.
  • Experimental: Nondiabetic/HFrEF Group
    40 patients non-diabetes mellitus group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin.

Primary Outcome Measure

Neopterin Concentration [ Time Frame: 3 month ]

Related Studies